Best Hospitals for Cardioversion Treatment in Bengaluru, India

Cardioversion is the therapeutic resetting of a pathological cardiac rhythm to normal sinus rhythm (NSR). The most common indication is atrial fibrillation, a disorganized atrial electrical activity affecting approximately 37 million people globally, which markedly elevates the risk of embolic stroke, heart failure, and hemodynamic compromise. In AFib, loss of coordinated atrial contraction reduces cardiac output by up to 20–30%, precipitating dyspnea, palpitations, fatigue, and in decompensated patients, cardiogenic shock. The CHA₂DS₂-VASc risk-scoring system is used universally to stratify thromboembolic risk prior to cardioversion planning.

• ELIGIBLE PATIENTS:
• Symptomatic atrial fibrillation (paroxysmal, persistent, or long-standing persistent) refractory to rate-control medications
• Atrial flutter with 2:1 or higher atrioventricular conduction causing hemodynamic symptoms
• Supraventricular tachycardias (SVTs) including AVNRT and AVRT not responsive to vagal maneuvers or adenosine
• Hemodynamically unstable tachyarrhythmias requiring urgent/emergent synchronized cardioversion
• +19 more

Electrical Cardioversion (synchronized DCCV):

The gold-standard procedure for elective rhythm restoration. Performed under short-acting intravenous sedation (propofol, midazolam with fentanyl, or etomidate) to ensure patient comfort. Biphasic waveform defibrillators are exclusively used in modern practice — delivering 120–200 joules, biphasic waveforms require significantly less energy than monophasic and achieve higher first-shock success rates (>85% first shock, >95% cumulative). Electrode placement uses the standard anterolateral or anteroposterior configuration; anteroposterior positioning is preferred for patients with persistent AFib or elevated BMI due to superior transthoracic impedance. The defibrillator synchronizes the shock delivery to the R-wave of the ECG, preventing shock-on-T phenomenon that could induce ventricular fibrillation. Total procedure time: 15–30 minutes. Continuous cardiac monitoring and oxygen saturation monitoring are maintained throughout.

Pharmacological CARDIOVERSION:

Indicated for recent-onset AFib (<48 hours duration) in hemodynamically stable patients or as a bridge/adjunct to ECV. Agent selection is driven by structural heart disease status:

PHASE 1 — PRE-PROCEDURE PREPARATION (2–4 weeks before, if elective):

• GAF Healthcare coordinates a complete pre-procedural workup via telemedicine review of existing records before travel
• Anticoagulation initiation: If not already anticoagulated, a DOAC (apixaban, rivaroxaban) or warfarin is started; INR target 2.0–3.0 for warfarin-treated patients; DOACs are preferred for most patients
• Minimum 3 weeks of documented therapeutic anticoagulation required OR TEE exclusion of LAA thrombus
• Electrolyte correction, thyroid normalization, and optimization of comorbidities (blood pressure, heart failure)
• Pre-procedure fasting: 6 hours for solids, 2 hours for clear liquids (per ASA guidelines for sedation)
• Patient arrives at hospital on day of procedure; anesthesiology pre-assessment completed

PHASE 2 — THE PROCEDURE (Day 1):